Table 1 Pathological features of... | American Society of Hematology

Table 1

Pathological features of leukemias arising in mice transplanted with engineered hCD34⁺ HSPCs

No.	Oncogene insertion	Cell count prenuc. ×10⁶	In vitro culture, days	Latency, weeks	BM hCD45, %	Phenotype	Spleen, mg	Secondary Tx, pos/total inj.
1	AF9	1	21	9	75	AML	20	1/3
2	AF9	1.0	21	14	83	AML	40	0/2
3	AF9	1.5	1	33.5	87	AML	100	nd
4	AF9	1.2	0	14	75	MPAL	50	1/1
5	AF9	2.8	0	16	84	MPAL	40	1/1
6	AF9	3.3	1	20.5	82	MPAL	40	2/4
7	AF9	2.7	0	23	81	MPAL	20	1/1
8	AF9	1.5	0	8.5	90	ALL	180	nd
9	AF9	2.4	0	10	93	ALL	120	1/3
10	AF9	2.2	2	10.5	48	ALL	140	nd
11	AF9	1.5	1	32	77	ALL	70	nd
12	AF9	2	2	29	72	ALL	110	nd
13	ENL2	3	0	11.5	95	ALL	80	2/2
14	ENL2	2.7	0	28	92	ALL	120	nd
15	ENL7	3.6	1	8	90	ALL	80	1/2
16	ENL7	2.7	0	14.5	95	ALL	170	nd
17	ENL7	0.75	1	30.5	82	ALL	30	nd

No.	Oncogene insertion	Cell count prenuc. ×10⁶	In vitro culture, days	Latency, weeks	BM hCD45, %	Phenotype	Spleen, mg	Secondary Tx, pos/total inj.
1	AF9	1	21	9	75	AML	20	1/3
2	AF9	1.0	21	14	83	AML	40	0/2
3	AF9	1.5	1	33.5	87	AML	100	nd
4	AF9	1.2	0	14	75	MPAL	50	1/1
5	AF9	2.8	0	16	84	MPAL	40	1/1
6	AF9	3.3	1	20.5	82	MPAL	40	2/4
7	AF9	2.7	0	23	81	MPAL	20	1/1
8	AF9	1.5	0	8.5	90	ALL	180	nd
9	AF9	2.4	0	10	93	ALL	120	1/3
10	AF9	2.2	2	10.5	48	ALL	140	nd
11	AF9	1.5	1	32	77	ALL	70	nd
12	AF9	2	2	29	72	ALL	110	nd
13	ENL2	3	0	11.5	95	ALL	80	2/2
14	ENL2	2.7	0	28	92	ALL	120	nd
15	ENL7	3.6	1	8	90	ALL	80	1/2
16	ENL7	2.7	0	14.5	95	ALL	170	nd
17	ENL7	0.75	1	30.5	82	ALL	30	nd

inj., injected; nd, not determined; pos, positive; prenuc., prenucleofection; Tx, transplantation.